| Literature DB >> 35390769 |
John A Thompson1, Bryan J Schneider2, Julie Brahmer3, Amaka Achufusi4, Philippe Armand5, Meghan K Berkenstock3, Shailender Bhatia1, Lihua E Budde6, Saurin Chokshi7, Marianne Davies8, Amro Elshoury9, Yaron Gesthalter10, Aparna Hegde11, Michael Jain12, Benjamin H Kaffenberger13, Melissa G Lechner14, Tianhong Li15, Alissa Marr16, Suzanne McGettigan17, Jordan McPherson18, Theresa Medina19, Nisha A Mohindra20, Anthony J Olszanski21, Olalekan Oluwole22, Sandip P Patel23, Pradnya Patil24, Sunil Reddy25, Mabel Ryder26, Bianca Santomasso27, Scott Shofer28, Jeffrey A Sosman20, Yinghong Wang29, Vlad G Zaha30, Megan Lyons31, Mary Dwyer31, Lisa Hang31.
Abstract
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35390769 DOI： 10.6004/jnccn.2022.0020
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908